Zoetis Inc. (ZTS)

Total return at 5 years: 17.1%/year = 14.4% appreciation + 2.7% dividend. The target price ($148) is ex-dividend; the $13 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $146 · Multiples $130) exceeds the market price ($76).

Today — with margin of safety: at $76 trades ~42.0% below its value discounted to today (~$130) — the wide discount we require (≥38%, equivalent to a ~15% annual return); the risk is covered by the margin, not the rate.

At 5 years — Muy infravalorado: the target price ($148) plus dividends yield above the required average return (10%) — the business compounds.

The bridge: the return at 5 years comfortably exceeds the risk-free rate (4.5%) — and the discount reaches the required margin of safety.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($76) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-9.1%/year) than we project (5.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$1.4 bn of owner earnings in year 5 (vs ~$2.8 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Zoetis is valued at the enterprise level, on a multiple of after-tax operating income and on the adjusted base the company guides: being a metric taken before interest, the cash ($1,941 million) and the debt ($9,045 million) enter the bridge and the funding is charged only once. The year-0 adjusted base is the $2,672 million of net income for the rolling period ended 31-Mar-2026 plus $88 million of non-recurring items declared in the FY2025 10-K (restructuring $51M, impairments $27M, the process transformation program $29M and a loss on the sale of medicated feed additives $3M, net at the real effective rate of 20.4%): $2,760 million, or a 29.0% margin. Year 1 does not come from the 10-K trajectory but from the current guidance the company published in the 8-K of 7-May-2026: revenue of US$9.68-9.96 billion and adjusted earnings per share of US$6.85-7.00. The base case takes the midpoint of both anchors at once (US$9.82 billion × a 29.3% margin ≈ US$2.88 billion, or around US$6.93 per share on the period's average share count), and the bear and bull cases anchor to the extremes of the same guided range. The path is trough-and-recovery shaped —+3.0% · +4.0% · +4.5% · +5.0% · +5.0%— and not a monotonic deceleration: year 1 picks up the contraction in the US companion animal segment and the pricing pressure that prompted the guidance cut, and the following years return toward animal health category growth as that comparison annualizes and the drag from the medicated feed additives divestiture (−3 points of volume in 2025) disappears. Maintenance capex is set at 88% of total capex, the split that corresponds to nearly flat revenue under the Greenwald criterion (growth capex ≈ fixed assets over sales × change in sales). Buybacks are modeled explicitly: the observed net reduction was from 470.4 to 422.4 million shares over three and a half years, but the projection is capped at −3.0% a year, which is what owner flow supports after the dividend, and not the recent rate, which was funded partly with debt issuance. With explicit buybacks cash does not accumulate and the retained surplus is redeployed into the operation.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $148 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $76, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $148 in 5 years plus $13 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $130. Against the current market price ($76), the margin of safety is 42.0% (trades below the maximum → there is margin) and the total return at that price would be 17.1% annually.

• Entry multiple. 14× on adjusted earnings, far below where the stock traded historically and below the archetype ceiling.
• Exit multiple. 17×, midrange of the 14× to 22× band; return does not hinge on multiple expansion.
• Scenario asymmetry. The adverse scenario with sustained price pressure and generic erosion still delivers positive return; the favorable case more than triples the price.
• Discount source identified. May 7, 2026 guidance cut and de-rating of a historically elevated multiple: there is a concrete motivated seller, not a low multiple without cause.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (84%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Return on invested capital. 27.5% on real invested capital from the balance sheet, comfortably above the 10% bar.
• Cash-backed return. Operating cash flow of US$2,887 million versus net income of US$2,616 million in the trailing period to Jun 30, 2026: earnings are collected.
• Stock-based compensation. US$91 million, 1.0% of revenues and 4.1% of free cash flow; expensed within earnings and low materiality.
• Reinvestment runway. Capex barely exceeds depreciation with revenues nearly flat: organic reinvestment does not absorb much capital and the excess is returned.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Zoetis revenues decompose into price per volume on a veterinary prescription portfolio. In 2025 the 3% operating growth was built with approximately 4 points of price, 1 point of volume from online products and 1 point from key franchises, against 3 points of drag from the divestment of medicated feed additives and 1 point headwind from foreign exchange. The company does not publish unit volumes, so the geographic segment split and disclosed price contribution are the available indicators.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Starting point of the path. Anchored in the May 7, 2026 8-K guidance, reading both anchors of the range at once: revenues and adjusted EPS.
• Growth decomposition. Approximately 4 points of price and 2 of volume in 2025, against 3 points of drag from divestment and 1 from foreign exchange.
• International growth. The International segment advanced 3.7% in 2025 despite foreign exchange headwind, but benefited from a pull-forward that does not repeat.
• Five-year landing. Projected at 5.0% annually in year 5, within the compounder-with-runway band and below the company's historical pace.

• Demand recurrence and predictability. Repeated veterinary prescription on parasiticides, vaccines and dermatology; annual and non-discretionary use in practice.
• Differentiated or generic product. Portfolio with best-in-class firsts (Apoquel, Cytopoint, Librela) and a brand that retains sales after patent expiration.
• Pricing power. Contributed approximately 4 points of operating growth in 2025, but the 11% companion animal contraction in the United States suggests it is starting to hit a ceiling.
• Product and channel concentration. The five main lines are 42% of revenue and the largest customer around 16%; dependence is high at both ends.
• Capital cycle in the industry. No large-scale generic capital entry: each product opportunity is small and distribution requires direct technical education, which restrains return compression.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)16.1x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 84% of ROIC
• ✓Value creation (ROIC − 10% bar)+18pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 1.1x
• !Float / working capitalConsumes cash $0.5 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.0% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Interest coverage. Expense of US$222 million in 2025 against operating income of approximately US$3.567 billion: covered about 16 times.
• Debt to cash flow. Gross debt of US$9.045 billion and cash of US$1.941 billion against operating cash flow of US$2.790 billion: net debt near 2.5×.
• Book equity. US$3.233 billion, small relative to debt as a result of returning more by buyback than retained.
• Cash conversion. Free cash flow of US$2,316 million versus net income of US$2,616 million in the trailing period to Jun 30, 2026, with limited growth capex.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Patrimonial alignment. Directors and executives as a group own less than 1% per the 2026 proxy; no controlling shareholder or founding block.
• Buyback quality. US$3.200 billion in 2025 at an average price well above current levels and partly debt-financed: capital returned dear.
• Portfolio discipline. The 2024 divestment of feed additives gave up 3 points of volume for better mix, a decision consistent with the moat.
• Continuity of leadership. Chief executive developed within the company since 2012, with participation in the 2013 initial public offering.

• Motivated seller: on May 7, 2026 the company missed consensus (Q1 revenue US$2.26 billion versus US$2.31 expected; EPS US$1.53 versus US$1.61) and cut annual revenue and adjusted EPS guidance. The stock fell over 20% in a single session.
• Motivated seller: de-rating of a historically elevated multiple. Zoetis traded as a high-growth compounder and the stock sank, a shift in expectations faster than business deterioration.
• Missing buyers: the 11% contraction in the companion animal segment in the United States is being read as structural cycle break in pet premiumization, when consolidated revenue is still growing and the International segment advanced 3.7% in 2025.

The crash alert is resolved: the event the 10-K could not contain is the May 7, 2026 8-K with the guidance cut. This analysis's projection path starts from that guidance, not the filing trajectory, so the deterioration is already built into the base.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at +7%/year (+40% total): the margin of safety protects the downside. The bull (+26%/year, +214% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Generic erosion. The filing quantifies 39% and 66% declines in Rimadyl chewable and Draxxin after generic entry; Excede, Naxcel and Cerenia patents expire between 2025 and 2028.
• Product concentration. The five main lines concentrate about 42% of 2025 revenue and the top ten around 57%.
• Channel power. The largest distributor is about 16% of revenue and consolidation of clinics and producers pressures price downward.
• Single-source manufacturing. Complex processes and single-source on 21 proprietary plants and more than 90 contract manufacturers, with a precedent of product rationing.
• Foreign exchange exposure. About 42% of revenue in currencies other than the dollar, with operations subject to exchange controls and repatriation restrictions.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  A wide moat and ROIC 28% above the 10% bar, with a +42% margin → a quality business at a good price.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 5% at a multiple/growth of 2.8 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 11% (EBIT/EV) + ROIC 28% → makes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -9% vs our 5%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor +4%/yr, bull-scenario ceiling +23%/yr over 5y and a +42% margin → capital protected, asymmetry in your favor.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, stable; sources: intangibles, efficient scale, switching costs, cost advantage → passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -9%, within what we project (5%) — the story squares with the numbers.